TransMedics Group, Inc.

TransMedics Group reported a 20.7% increase in total revenue to $189.9 million for the second quarter of 2026, and a 20.9% increase to $363.9 million for the first six months of 2026. However, net income for Q2 2026 significantly decreased by 57.9% to $14.7 million, with diluted EPS falling to $0.41. The company also saw a 63.7% drop in net income for the first half of the year to $22.0 million. This decline in profitability occurred amidst increased operating expenses, including research, development, and clinical trials, and a substantial increase in finance lease liabilities and property, plant, and equipment related to new facilities.

TransMedics Group, Inc. held its 2026 Annual Meeting of Shareholders on May 20, 2026. Shareholders elected all eight director nominees, including Waleed Hassanein, M.D. and Stephanie Lovell, to serve until the 2027 Annual Meeting. Additionally, shareholders approved the compensation of named executive officers on an advisory basis and ratified the amendment to the 2019 Stock Incentive Plan. PricewaterhouseCoopers LLP was also ratified as the independent auditor for the fiscal year ending December 31, 2026.

TransMedics Group reported a 21% increase in total revenue to $173.9 million for Q1 2026, driven by growth in both product and service revenue. However, net income significantly decreased by 72% to $7.3 million, and diluted EPS fell to $0.20. The company also noted a material weakness in its internal control over financial reporting and a substantial increase in finance lease liabilities, while improving net cash from operating activities.